{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T08:56:29Z","timestamp":1789721789908,"version":"4.0.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T00:00:00Z","timestamp":1781913600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T00:00:00Z","timestamp":1781913600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      The REASURE study investigated imaging biomarkers in men receiving\n                      <jats:sup>223<\/jats:sup>\n                      Ra treatment for prostate cancer bone metastases. We used REASURE data to compare and contrast the roles of [\n                      <jats:sup>18<\/jats:sup>\n                      F]NaF PET\/CT measurements of maximum standardised uptake value (SUVmax) and bone metabolic flux (Ki) as markers of response.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Thirty-four men with prostatic bone metastases received up to six cycles of\n                      <jats:sup>223<\/jats:sup>\n                      Ra (55 or 88\u00a0kBq\/kg) at four-weekly intervals. Whole-body diffusion-weighted MRI and [\n                      <jats:sup>18<\/jats:sup>\n                      F]NaF PET\/CT images were acquired at baseline and 4, 12, and 24 weeks later. Values of the apparent diffusion coefficient (ADC, a measure of tumour response), SUVmax, and a novel surrogate measurement of Ki using a PET\/CT SUV measurement in the left ventricle were monitored in up to 5 bone metastases in each participant. Multilinear regression analysis (MLR) was performed to determine if changes in ADC were predicted by changes in SUVmax or Ki. Radium dose and baseline SUVmax were additional independent variables.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      ADC values increased throughout the study, while SUVmax and Ki decreased. MLR analysis showed that baseline SUVmax and\n                      <jats:sup>223<\/jats:sup>\n                      Ra dose predicted ADC response (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001 and\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.01, respectively). Changes in SUVmax and Ki at 4, 12, and 24 weeks failed to predict the changes in ADC, showing decoupling between MRI and PET\/CT measurements as markers of response. Changes in Ki were a highly significant predictor of changes in SUVmax (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001), reflecting the strong correlation between these two measurements.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Baseline SUVmax was the best predictor of ADC response, followed by\n                      <jats:sup>223<\/jats:sup>\n                      Ra dose. Changes in SUVmax and Ki failed to predict changes in ADC, suggesting that the changes in the PET\/CT variables reflected the effect of\n                      <jats:sup>223<\/jats:sup>\n                      Ra uptake on osteoblasts rather than a tumoricidal effect. A decrease in SUVmax seen on post-therapy [\n                      <jats:sup>18<\/jats:sup>\n                      F]NaF PET\/CT scans should not be interpreted as evidence of tumour regression.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration<\/jats:title>\n                    <jats:p>ISRCTN ISRCTN17805587. Registered 21\/01\/15.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00259-026-08009-8","type":"journal-article","created":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T23:22:22Z","timestamp":1781911342000},"page":"6536-6548","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Does 18F-sodium fluoride PET\/CT have a role in the assessment of response to 223Ra therapy in men with prostatic bone metastases?"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1530-5267","authenticated-orcid":false,"given":"Glen M.","family":"Blake","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Donners","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelia E.B.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly","family":"Tovey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aude","family":"Espinasse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew D.","family":"Blackledge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sue","family":"Chua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dow-Mu","family":"Koh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilia","family":"Nuzzaci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Tunariu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher C.","family":"Parker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary J.R.","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,20]]},"reference":[{"issue":"12","key":"8009_CR1","doi-asserted-by":"publisher","first-page":"4451","DOI":"10.1158\/1078-0432.CCR-04-2244","volume":"11","author":"S Nilsson","year":"2005","unstructured":"Nilsson S, Larsen RH, Foss\u00e5 SD, Balteskard L, Borch KW, Westlin J-E, et al. First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases. Clin Cancer Res. 2005;11(12):4451\u20139.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"8009_CR2","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/S1470-2045(07)70147-X","volume":"8","author":"S Nilsson","year":"2007","unstructured":"Nilsson S, Franz\u00e9n L, Parker C, Tyrrell C, Blom R, Tennvall J, et al. Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. Lancet Oncol. 2007;8(7):587\u201394.","journal-title":"Lancet Oncol"},{"issue":"3","key":"8009_CR3","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa1213755","volume":"369","author":"C Parker","year":"2013","unstructured":"Parker C, Nilsson S, Heinrich D, Helle SI, O\u2019Sullivan JM, Foss\u00e5 SD, et al. Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer. N Engl J Med. 2013;369(3):213\u201323.","journal-title":"N Engl J Med"},{"issue":"5","key":"8009_CR4","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1007\/s00259-017-3900-4","volume":"45","author":"TD Poeppel","year":"2018","unstructured":"Poeppel TD, Handkiewicz-Junak D, Andreeff M, Becherer A, Bockisch A, Fricke E, et al. EANM guideline for radionuclide therapy with radium-223 of metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2018;45(5):824\u201345.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"8009_CR5","doi-asserted-by":"publisher","first-page":"176","DOI":"10.2967\/jnmt.123.265936","volume":"51","author":"AR Pantel","year":"2023","unstructured":"Pantel AR, Eiber M, Beyder DD, Kendi AT, Laforest R, Rauscher I, et al. SNMMI Procedure Standard\/EANM Practice Guideline for Palliative Nuclear Medicine Therapies of Bone Metastases. J Nucl Med Technol. 2023;51(3):176\u201387.","journal-title":"J Nucl Med Technol"},{"issue":"5","key":"8009_CR6","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1093\/annonc\/mdw065","volume":"27","author":"S Nilsson","year":"2016","unstructured":"Nilsson S, Cislo P, Sartor O, Vogelzang NJ, Coleman RE, O\u2019Sullivan JM, et al. Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study. Ann Oncol. 2016;27(5):868\u201374.","journal-title":"Ann Oncol"},{"issue":"12","key":"8009_CR7","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1097\/MNM.0000000000002050","volume":"46","author":"M Randhawa","year":"2025","unstructured":"Randhawa M, Buchanan G, Stratton IM, Race G, Challapalli A, Bottomley D, et al. UK real-world data of radium-223 dichloride in metastatic prostate cancer. Nucl Med Commun. 2025;46(12):1155\u201362.","journal-title":"Nucl Med Commun"},{"issue":"2","key":"8009_CR8","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1111\/cas.70293","volume":"117","author":"M Shiota","year":"2026","unstructured":"Shiota M, Tatarano S, Kamba T, Kamoto T, Igawa T, Masumori N, et al. Effectiveness and Safety of Radium-223 for Bone-Metastatic Castration-Resistant Prostate Cancer: The KYUCOG-1901 Study. Cancer Sci. 2026;117(2):501\u201310.","journal-title":"Cancer Sci"},{"issue":"1","key":"8009_CR9","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1053\/j.semnuclmed.2025.11.020","volume":"56","author":"C Torricelli","year":"2026","unstructured":"Torricelli C, Almeida L, Etchebehere E. Assessing therapeutic response to Radium-223. Semin Nucl Med. 2026;56(1):105\u201318.","journal-title":"Semin Nucl Med"},{"issue":"4","key":"8009_CR10","doi-asserted-by":"publisher","first-page":"413","DOI":"10.3390\/diagnostics5040413","volume":"5","author":"K Kairemo","year":"2015","unstructured":"Kairemo K, Joensuu T. Radium-223-Dichloride in Castration Resistant Metastatic Prostate Cancer-Preliminary Results of the Response Evaluation Using F-18-Fluoride PET\/CT. Diagnostics (Basel). 2015;5(4):413\u201327.","journal-title":"Diagnostics (Basel)"},{"key":"8009_CR11","doi-asserted-by":"publisher","first-page":"101993","DOI":"10.1016\/j.eclinm.2023.101993","volume":"60","author":"CS Higano","year":"2023","unstructured":"Higano CS, George DJ, Shore ND, Sartor O, Miller K, Conti PS, et al. Clinical outcomes and treatment patterns in REASSURE: planned interim analysis of a real-world observational study of radium-223 in metastatic castration-resistant prostate cancer. EClinicalMedicine. 2023;60:101993. https:\/\/doi.org\/10.1016\/j.eclinm.2023.101993 . eCollection 2023 Jun.","journal-title":"EClinicalMedicine"},{"issue":"6","key":"8009_CR12","doi-asserted-by":"publisher","first-page":"pkad077","DOI":"10.1093\/jncics\/pkad077","volume":"7","author":"C Parker","year":"2023","unstructured":"Parker C, Tunariu N, Tovey H, Alonzi R, Blackledge MD, Cook GJR, et al. Radium-223 in metastatic castration-resistant prostate cancer: whole-body diffusion-weighted magnetic resonance imaging scanning to assess response. JNCI Cancer Spectr. 2023;7(6):pkad077.","journal-title":"JNCI Cancer Spectr"},{"issue":"2","key":"8009_CR13","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1007\/s00330-023-10172-7","volume":"34","author":"R Donners","year":"2024","unstructured":"Donners R, Tunariu N, Tovey H, Hall E, Chua S, Cook G, et al. The value of baseline 18F\u2013sodium fluoride and 18F\u2013choline PET activity for identifying responders to radium\u2013223 treatment in castration\u2013resistant prostate cancer bone metastases. Eur Radiol. 2024;34(2):1146\u201354.","journal-title":"Eur Radiol"},{"issue":"2","key":"8009_CR14","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1097\/RLI.0000000000000415","volume":"53","author":"R Perez-Lopez","year":"2018","unstructured":"Perez-Lopez R, Nava Rodrigues D, Figueiredo I, Mateo J, Collins DJ, Koh D-M, et al. Multiparametric Magnetic Resonance Imaging of Prostate Cancer Bone Disease: Correlation with Bone Biopsy Histological and Molecular Features. Invest Radiol. 2018;53(2):96\u2013102.","journal-title":"Invest Radiol"},{"issue":"6","key":"8009_CR15","doi-asserted-by":"publisher","first-page":"448","DOI":"10.5152\/tud.2021.21274","volume":"47","author":"M Scialpi","year":"2021","unstructured":"Scialpi M, Martorana E, Scialpi P, D\u2019Andrea A, Mancioli FM, Mignogna M, et al. MRI apparent diffusion coefficient (ADC): A biomarker for prostate cancer after radiation therapy. Turk J Urol. 2021;47(6):448\u201351.","journal-title":"Turk J Urol"},{"issue":"4","key":"8009_CR16","doi-asserted-by":"publisher","first-page":"e607","DOI":"10.1016\/j.crad.2023.12.022","volume":"79","author":"FB Franco","year":"2024","unstructured":"Franco FB, Leeman JE, Fedorov A, Vangel M, Fennessy FM. Early change in apparent diffusion coefficient as a predictor of response to neoadjuvant androgen deprivation and external beam radiation therapy for intermediate- to high-risk prostate cancer. Clin Radiol. 2024;79(4):e607\u201315.","journal-title":"Clin Radiol"},{"key":"8009_CR17","doi-asserted-by":"publisher","first-page":"112788","DOI":"10.1016\/j.ejrad.2026.112788","volume":"199","author":"P Wibulpolprasert","year":"2026","unstructured":"Wibulpolprasert P, Bihan DL, Leelarujijaroen P, Kampaengtip A, Kijvikai K, Worawichawong S, Phongkitkarun S. Potential of the signature index (S-index), a diffusion MRI Biomarker, to enhance diagnosis of clinically significant prostate cancer and decrease the rate of unnecessary biopsies. Eur J Radiol. 2026;199:112788.","journal-title":"Eur J Radiol"},{"issue":"1","key":"8009_CR18","doi-asserted-by":"publisher","first-page":"4","DOI":"10.2967\/jnumed.111.093443","volume":"53","author":"M Vanderhoek","year":"2012","unstructured":"Vanderhoek M, Perlman SB, Jeraj R. Impact of the definition of peak standardized uptake value on quantification of treatment response. J Nucl Med. 2012;53(1):4\u201311.","journal-title":"J Nucl Med"},{"issue":"4","key":"8009_CR19","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/S0001-2998(84)80003-3","volume":"14","author":"BJ McNeil","year":"1984","unstructured":"McNeil BJ. Value of bone scanning in neoplastic disease. Semin Nucl Med. 1984;14(4):227\u201386.","journal-title":"Semin Nucl Med"},{"issue":"3","key":"8009_CR20","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1053\/snuc.2001.23527","volume":"31","author":"GJR Cook","year":"2001","unstructured":"Cook GJR, Fogelman I. The role of nuclear medicine in monitoring treatment in skeletal malignancy. Semin Nucl Med. 2001;31(3):206\u201311.","journal-title":"Semin Nucl Med"},{"issue":"3","key":"8009_CR21","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/pcan.2017.6","volume":"20","author":"D Keizman","year":"2017","unstructured":"Keizman D, Fosboel MO, Reichegger H, Peer A, Rosenbaum E, Desax MC, et al. Imaging response during therapy with radium-223 for castration-resistant prostate cancer with bone metastases-analysis of an international multicenter database. Prostate Cancer Prostatic Dis. 2017;20(3):289\u201393.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"8009_CR22","doi-asserted-by":"publisher","first-page":"175883592098765","DOI":"10.1177\/1758835920987654","volume":"13","author":"V Conteduca","year":"2021","unstructured":"Conteduca V, Poti G, Caroli P, Russi S, Brighi N, Lolli C, et al. Flare phenomenon in prostate cancer: recent evidence on new drugs and next generation imaging. Ther Adv Med Oncol. 2021;13:1758835920987654.","journal-title":"Ther Adv Med Oncol"},{"issue":"5","key":"8009_CR23","first-page":"633","volume":"33","author":"RA Hawkins","year":"1992","unstructured":"Hawkins RA, Choi Y, Huang S-C, Hoh CK, Dahlbom M, Schiepers C, et al. Evaluation of the skeletal kinetics of fluorine-18-fluoride ion with PET. J Nucl Med. 1992;33(5):633\u201342.","journal-title":"J Nucl Med"},{"issue":"6","key":"8009_CR24","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1002\/jbmr.1862","volume":"28","author":"ML Frost","year":"2013","unstructured":"Frost ML, Moore AE, Siddique M, Blake GM, Laurent D, Borah B, et al. \u00b9\u2078F-fluoride PET as a noninvasive imaging biomarker for determining treatment efficacy of bone active agents at the hip: a prospective, randomized, controlled clinical study. J Bone Min Res. 2013;28(6):1337\u201347.","journal-title":"J Bone Min Res"},{"issue":"4","key":"8009_CR25","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1002\/mp.16125","volume":"50","author":"T Puri","year":"2023","unstructured":"Puri T, Frost ML, Moore AEB, Cook GJR, Blake GM. Input function and modeling for determining bone metabolic flux using [18F] sodium fluoride PET imaging: A step-by-step guide. Med Phys. 2023;50(4):2071\u201388.","journal-title":"Med Phys"},{"issue":"3","key":"8009_CR26","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.bone.2011.05.031","volume":"49","author":"GM Blake","year":"2011","unstructured":"Blake GM, Siddique M, Frost ML, Moore AEB, Fogelman I. Radionuclide studies of bone metabolism: do bone uptake and bone plasma clearance provide equivalent measurements of bone turnover? Bone. 2011;49(3):537\u201342.","journal-title":"Bone"},{"issue":"3","key":"8009_CR27","doi-asserted-by":"publisher","first-page":"322","DOI":"10.2967\/jnumed.118.208710","volume":"60","author":"GK Azad","year":"2019","unstructured":"Azad GK, Siddique M, Taylor B, Green A, O\u2019Doherty J, Gariani J, et al. Is Response Assessment of Breast Cancer Bone Metastases Better with Measurement of 18F-Fluoride Metabolic Flux Than with Measurement of 18F-Fluoride PET\/CT SUV? J Nucl Med. 2019;60(3):322\u20137.","journal-title":"J Nucl Med"},{"key":"8009_CR28","unstructured":"ISRCTN.Radium-223. Evaluation of Activity and Surrogate Response 2015 [updated 07\/02\/2021]. https:\/\/www.isrctn.com\/ISRCTN17805587. Accessed 10 May 2026."},{"issue":"2","key":"8009_CR29","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s00259-011-1966-y","volume":"39","author":"M Siddique","year":"2012","unstructured":"Siddique M, Blake GM, Frost ML, Moore AE, Puri T, Marsden PK, Fogelman I. Estimation of regional bone metabolism from whole-body18F-fluoride PET static images. Eur J Nucl Med Mol Imaging. 2012;39(2):337\u201343.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"8","key":"8009_CR30","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1097\/MNM.0b013e3283550275","volume":"33","author":"GM Blake","year":"2012","unstructured":"Blake GM, Siddique M, Puri T, Frost ML, Moore AE, Cook GJ, Fogelman I. A semi-population input function for quantifying static and dynamic 18F-fluoride PET scans. Nucl Med Commun. 2012;33(8):881\u20138.","journal-title":"Nucl Med Commun"},{"issue":"9","key":"8009_CR31","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/BF00254749","volume":"12","author":"GM Blake","year":"1986","unstructured":"Blake GM, Zivanovic MA, McEwan AJ, Ackery DM. Sr-89 therapy: strontium kinetics in disseminated carcinoma of the prostate. Eur J Nucl Med. 1986;12(9):447\u201354.","journal-title":"Eur J Nucl Med"},{"issue":"19","key":"8009_CR32","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.3390\/diagnostics14192229","volume":"14","author":"E Askari","year":"2024","unstructured":"Askari E, Shakeri S, Roustaei H, Fotouhi M, Sadeghi R, Harsini S, et al. Superscan Pattern on Bone Scintigraphy: A Comprehensive Review. Diagnostics (Basel). 2024;14(19):2229.","journal-title":"Diagnostics (Basel)"},{"key":"8009_CR33","unstructured":"Statistics Kingdom. (2017). Multiple Linear Regression Calculator (web application). https:\/\/www.statskingdom.com\/410multi_linear_regression.html (accessed 10 May 2026)."},{"key":"8009_CR34","unstructured":"Lowry R. (1998). VassarStats (website for statistical computation). http:\/\/vassarstats.net (accessed 10 May 2026)."},{"issue":"10","key":"8009_CR35","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1097\/RLU.0b013e318148b1dd","volume":"32","author":"G Gnanasegaran","year":"2007","unstructured":"Gnanasegaran G, Moore AE, Blake GM, Vijayanathan S, Clarke SE, Fogelman I. Atypical Paget\u2019s disease with quantitative assessment of tracer kinetics. Clin Nucl Med. 2007;32(10):765\u20139.","journal-title":"Clin Nucl Med"},{"issue":"2","key":"8009_CR36","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1097\/00004032-197302000-00001","volume":"24","author":"JH Marshall","year":"1973","unstructured":"Marshall JH, Lloyd EL, Rundo J, Liniecki J, Marotti G, Mays CW, et al. Alkaline earth metabolism in adult man. Health Phys. 1973;24(2):125\u2013221.","journal-title":"Health Phys"},{"key":"8009_CR37","doi-asserted-by":"crossref","unstructured":"Blake GM, Fogelman I. Bone Radionuclide Imaging, Quantitation and Bone Densitometry. In: McCready R, Gnanasegaran G, Bomanji JB, editors. A History of Radionuclide Studies in the UK. Springer International Publishing AG Switzerland; 2016. pp. 111\u201320.","DOI":"10.1007\/978-3-319-28624-2_15"},{"issue":"11","key":"8009_CR38","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1093\/annonc\/mdz270","volume":"30","author":"G De Vincentis","year":"2019","unstructured":"De Vincentis G, Gerritsen W, Gschwend JE, Hacker M, Lewington V, O\u2019Sullivan JM, et al. Targeted Alpha Therapy Prostate Working Group. Advances in targeted alpha therapy for prostate cancer. Ann Oncol. 2019;30(11):1728\u201339.","journal-title":"Ann Oncol"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-08009-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-026-08009-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-08009-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T07:00:49Z","timestamp":1787986849000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-026-08009-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,20]]},"references-count":38,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["8009"],"URL":"https:\/\/doi.org\/10.1007\/s00259-026-08009-8","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,20]]},"assertion":[{"value":"2 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The article was modified to correct the layout of Table 2.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The REASURE trial was registered with the ISRCTN registry (ISRCTN 17805587) and approved by the National Health Service Health Research Authority Committee London\u2013Surrey Borders Research Ethics Committee (14\/LO\/1385). Additional ethics approval was obtained for the present retrospective analysis of the REASURE scan data.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from all participants prior to their inclusion in the REASURE trial and the study was conducted in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no competing interests to declare that are relevant to the content of this article.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The scientific guarantor of this publication is Professor Glen Blake.","order":4,"name":"Ethics","label":"Guarantor","group":{"name":"EthicsHeading","label":"Declarations"}}]}}